Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNABW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ginkgo Bioworks Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ginkgo Bioworks Holdings's regulatory disclosures and financial reporting.
Ginkgo Bioworks Holdings Inc: The Vanguard Group filed an Amendment No. 5 to its Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of Ginkgo Bioworks common stock. The filing explains an internal realignment effective 01/12/2026 that disaggregated certain Vanguard subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries under SEC Release No. 34-39538.
DNA submitted a Form 144 notice concerning Class A shares. The filing shows 708 Class A shares tied to a Restricted Stock Vesting event on 03/13/2026, with Fidelity Brokerage Services listed as broker. The filing also records a prior sale of 972 Class A shares on 01/20/2026 by Steve Coen.
DNA filing reports notices under Rule 144 to sell Class A shares. The filing lists two reported transactions by Austin Che of 2,200 Class A shares on 01/07/2026 and 02/04/2026, and earlier restricted stock vesting entries dated 10/18/2022 (888 shares) and 10/20/2022 (1,312 shares).
The entries identify Fidelity Brokerage Services LLC and include per-transaction numeric figures (2200) and associated monetary figures shown in the excerpt. This notice-style filing documents planned or reported dispositions; timing and cash-flow treatment are as stated in the entries.
Ginkgo Bioworks Holdings reported 2025 revenue of $170.2 million, down from $227.0 million in 2024, as both cell engineering and biosecurity revenue declined. The company’s net loss narrowed to $312.8 million from $547.0 million, helped by large reductions in research and development and general and administrative expenses.
R&D spending fell to $243.8 million and G&A to $183.3 million, reflecting a restructuring begun in 2024, lower headcount and reduced facilities and professional costs. Adjusted EBITDA improved to a loss of $167.0 million from a loss of $293.3 million, showing progress but continued heavy cash burn.
Biosecurity service revenue declined to $37.4 million on weaker government work, while new cell engineering tools such as Datapoints and automation systems drove higher "cost of other revenue" as those offerings scaled. The company ended 2025 with $167.2 million in cash and equivalents and $255.4 million in marketable securities and believes this liquidity will fund operations for at least 12 months.
Ginkgo Bioworks Holdings, Inc. reported weaker 2025 revenue alongside significantly reduced losses and a major strategic shift. Total revenue for 2025 was $170.2 million, down from $227.0 million (a 25% decline), with Cell Engineering revenue falling to $132.7 million and Biosecurity revenue to $37.4 million. Despite this, the GAAP net loss narrowed sharply to $(312.8) million from $(547.0) million, and Adjusted EBITDA improved to $(167.0) million from $(293.3) million, reflecting lower operating expenses and restructuring benefits.
The company ended 2025 with $423 million in cash, cash equivalents and marketable securities, down from higher prior-year levels, and guided for 2026 total cash burn of $(150)–$(125) million. Ginkgo plans to divest its non‑core biosecurity business to investors in exchange for a minority equity stake, turning it into a standalone private company, while refocusing the business on autonomous labs. Management highlighted expansion of its frontier autonomous lab in Boston, new collaboration results with OpenAI showing a 40% improvement in cell‑free protein synthesis, and a $47 million autonomous lab contract with Pacific Northwest National Laboratory as key proof points for the new strategy.
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Baillie Gifford reports beneficial ownership of 2,391,649 Class A shares, representing 4.93% of the class. It has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ginkgo Bioworks.
Form 144 discloses that holder Austin Che intends to sell 2,200 Class A shares through Fidelity Brokerage Services LLC on or about 02/04/2026 on the NYSE, with an aggregate market value of 19360.00. The issuer has 48,523,595 Class A shares outstanding.
The shares to be sold were acquired via restricted stock vesting from the issuer on 10/18/2022 (105 shares) and 10/19/2022 (2,095 shares), both as compensation. Over the past three months, Che sold 2,200 Class A shares on each of 11/12/2025, 12/10/2025, and 01/07/2026, for gross proceeds of 18700.00, 20988.00, and 20152.00, respectively.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and a small share sale. On January 16, 2026, RSUs covering 587, 156, and 1,062 units were converted into the same number of Class A common shares at an exercise price of $0 per share, reflecting equity awards that had been vesting over time. After these conversions, he held 9,293 Class A shares directly. On January 20, 2026, he sold 972 Class A shares at $8.917 per share, leaving him with 8,321 shares. According to the footnotes, the sale was made to cover tax withholding obligations related to the vesting of restricted stock and RSUs and did not represent a discretionary trade.
Ginkgo Bioworks Holdings (symbol DNA) filed a notice of proposed sales of restricted stock under Rule 144. The filing covers a planned sale of 972 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 8,667.23 and 48,523,595 Class A shares outstanding.
The 972 Class A shares were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation, with payment dated 01/16/2026. The notice also discloses that Steven Coen previously sold 736 Class A shares on 12/15/2025 for gross proceeds of 6,540.02.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.